Evidence map›Paper›PMID 31069578›Full record

ArticleCancer causes & control : CCC2019

Proceedings of the fourth international molecular pathological epidemiology (MPE) meeting.

Peter T Campbell, Christine B Ambrosone, Reiko Nishihara, Hugo J W L Aerts, Melissa Bondy, Nilanjan Chatterjee, Montserrat Garcia-Closas, Marios Giannakis, Jeffrey A Golden, Yujing J Heng and 20 more

Abstract readConference Proceedings
In one paragraph

Article in Cancer causes & control : CCC, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Peter T Campbell *Behavioral and Epidemiology Research Group, American Cancer Society, 250 Williams Street NW, Atlanta, GA, 30303, USA. peter.campbell@cancer.org.
Christine B Ambrosone *Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Reiko NishiharaProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 450 Brookline Ave, Room SM1036, Boston, MA, 02215, USA.
Hugo J W L AertsDepartments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Melissa BondyCancer Prevention and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Nilanjan ChatterjeeDepartment of Biostatistics, Bloomberg School of Public Health, Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Montserrat Garcia-ClosasDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Marios GiannakisDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Jeffrey A GoldenDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Yujing J HengDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
N Sertac KipSema4, Mount Sinai Icahn School of Medicine, Genetics & Genomic Sciences and Pathology, Branford, CT, USA.
Jill KoshiolDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
X Shirley LiuDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, 02215, USA.
Camila M Lopes-RamosDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Lorelei A MucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Jonathan A NowakDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Amanda I PhippsDepartment of Epidemiology, University of Washington, Seattle, WA, USA.
John QuackenbushDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Robert E SchoenDepartments of Medicine and Epidemiology, The University of Pittsburgh, Pittsburgh, PA, USA.
Lynette M ShollDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Rulla M TamimiDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Molin WangDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Matty P WeijenbergDepartment of Epidemiology, GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Kana WuDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Song YaoDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Kun-Hsing YuDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Xuehong ZhangChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Timothy R Rebbeck *Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Shuji Ogino *Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 450 Brookline Ave, Room SM1036, Boston, MA, 02215, USA. Shuji_ogino@dfci.harvard.edu.

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI Irene M. Ghobrial · 1985 to 2026
$330.6M
Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
Unraveling the Complexities of Risk and Mechanism in CancerR35CA220523 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI QUACKENBUSH, JOHN · 2018 to 2024
$6.0M
Accelerating Transdisciplinary Epidemiology of Colorectal CancerR35CA197735 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2015 to 2021
$6.0M
Quantitative Radiomics System Decoding the Tumor PhenotypeU24CA194354 · NCI · DANA-FARBER CANCER INST · PI AERTS, HUGO, QUACKENBUSH, JOHN · 2015 to 2019
$3.5M
Using Networks to Assign Gene Function in Lung DiseaseR01HL111759 · NHLBI · DANA-FARBER CANCER INST · PI QUACKENBUSH, JOHN, SILVERMAN, EDWIN K · 2012 to 2015
$3.4M
National Institutes of Health (US) 1R01 HL111759National Institutes of Health (US) 1R35 CA220523National Institutes of Health (US) NIH R35 CA197735National Institutes of Health (US) P30 CA006516NCI NIH HHS P30 CA006516NCI NIH HHS R35 CA197735NCI NIH HHS R35 CA220523NCI NIH HHS U24 CA194354NHLBI NIH HHS R01 HL111759
6 · The paper itself

Abstract

An important premise of epidemiology is that individuals with the same disease share similar underlying etiologies and clinical outcomes. In the past few decades, our knowledge of disease pathogenesis has improved, and disease classification systems have evolved to the point where no complex disease processes are considered homogenous. As a result, pathology and epidemiology have been integrated into the single, unified field of molecular pathological epidemiology (MPE). Advancing integrative molecular and population-level health sciences and addressing the unique research challenges specific to the field of MPE necessitates assembling experts in diverse fields, including epidemiology, pathology, biostatistics, computational biology, bioinformatics, genomics, immunology, and nutritional and environmental sciences. Integrating these seemingly divergent fields can lead to a greater understanding of pathogenic processes. The International MPE Meeting Series fosters discussion that addresses the specific research questions and challenges in this emerging field. The purpose of the meeting series is to: discuss novel methods to integrate pathology and epidemiology; discuss studies that provide pathogenic insights into population impact; and educate next-generation scientists. Herein, we share the proceedings of the Fourth International MPE Meeting, held in Boston, MA, USA, on 30 May-1 June, 2018. Major themes of this meeting included 'integrated genetic and molecular pathologic epidemiology', 'immunology-MPE', and 'novel disease phenotyping'. The key priority areas for future research identified by meeting attendees included integration of tumor immunology and cancer disparities into epidemiologic studies, further collaboration between computational and population-level scientists to gain new insight on exposure-disease associations, and future pooling projects of studies with comparable data.

Indexed as

EpidemiologyPathology, MolecularHumansNeoplasmsMeeting proceedingsMeeting reportMeeting summaryMolecular pathological epidemiologyPatho-epidemiology

Identifiers

PMID31069578
PMCPMC6614001

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.